Clinical trial
Combination Chemotherapy in Treating Patients With Advanced Cancer
NCT00003707 · The University of Texas Health Science Center at San Antonio, Other · Completed
Key facts
| NCT number | NCT00003707 |
|---|---|
| Title | Combination Chemotherapy in Treating Patients With Advanced Cancer |
| Official title | A Phase I, Maximum Tolerated Dose (MTD) Trial to Determine the Safety and Pharmacokinetics of Chronic Oral Administration of Farnesyl Transferase Inhibitor R115777 in Combination With Gemcitabine in Subjects With Advanced Incurable Cancer |
| Lead sponsor | The University of Texas Health Science Center at San Antonio, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, tipifarnib |
| Enrollment | 22 |
| Start date | Oct 1, 1998 |
| Primary completion | Nov 1, 2002 |
| Completion | Nov 1, 2002 |
| First posted | Jul 15, 2003 |
| Last update posted | Jun 28, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: